MicroRNA: a Prognostic Biomarker and a Possible Druggable Target for Circumventing Multidrug Resistance in Cancer Chemotherapy

Overview

Journal J Biomed Sci

Publisher Biomed Central

Specialty Biology

Date 2013 Dec 24

PMID 24358977

Citations 35

Authors

Kenneth K W To

Affiliations

Soon will be listed here.

Abstract

Multidrug resistance (MDR) is a major obstacle to successful cancer treatment. It is often associated with an increased efflux of a variety of structurally unrelated anticancer drugs by ATP-binding cassette (ABC) transporters including P-gp, ABCG2 and MRP1. MicroRNAs (miRNAs) are small non-coding RNAs that govern posttranscriptional regulation of target genes by interacting with specific sequences in their 3' untranslated region (3'UTR), thereby promoting mRNA degradation or suppressing translation. Accumulating evidence suggests that alterations in miRNAs contribute to resistance to anticancer drugs. While miRNAs are well-known to be dysregulated in cancer, recent literature revealed that miRNA levels in biological samples may be correlated with chemotherapy response. This review summarized the coordinated network by which miRNA regulated MDR transporters. The usefulness of miRNAs as prognostic biomarkers for predicting chemotherapeutic outcome is discussed. MiRNAs may also represent druggable targets for circumvention of MDR.

Citing Articles

Curcumin-Etoposide Synergy: Unveiling the Molecular Mechanisms of Enhanced Apoptosis and Chemoresistance Attenuation in Breast Cancer.

Jaberian Asl B, Afarin R, Hatami M, Dehghani Madiseh A, Roshanazadeh M, Rashidi M Iran J Pharm Res. 2025; 23(1):e150978.

PMID: 39834345 PMC: 11742740. DOI: 10.5812/ijpr-150978.

MiR-548c-3p through suppressing and increases the sensitivity of colorectal cancer cells to 5-fluorouracil.

Khalili E, Afgar A, Rajabpour A, Aghaee-Bakhtiari S, Jamialahmadi K, Teimoori-Toolabi L Heliyon. 2023; 9(11):e21775.

PMID: 38045156 PMC: 10692789. DOI: 10.1016/j.heliyon.2023.e21775.

miRNA-Based Technologies in Cancer Therapy.

Pagoni M, Cava C, Sideris D, Avgeris M, Zoumpourlis V, Michalopoulos I J Pers Med. 2023; 13(11).

PMID: 38003902 PMC: 10672431. DOI: 10.3390/jpm13111586.

MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies.

Kim T, Croce C Exp Mol Med. 2023; 55(7):1314-1321.

PMID: 37430087 PMC: 10394030. DOI: 10.1038/s12276-023-01050-9.

MiR-27a as a diagnostic biomarker and potential therapeutic target in systemic sclerosis.

Bayati P, Kalantari M, Assarehzadegan M, Poormoghim H, Mojtabavi N Sci Rep. 2022; 12(1):18932.

PMID: 36344812 PMC: 9640682. DOI: 10.1038/s41598-022-23723-7.

References

Blower P, Chung J, Verducci J, Lin S, Park J, Dai Z . MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther. 2008; 7(1):1-9. DOI: 10.1158/1535-7163.MCT-07-0573. View

Zhang S, Chen L, Jung E, Calin G . Targeting microRNAs with small molecules: from dream to reality. Clin Pharmacol Ther. 2010; 87(6):754-8. PMC: 3902962. DOI: 10.1038/clpt.2010.46. View

Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S . MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009; 361(15):1437-47. PMC: 2786938. DOI: 10.1056/NEJMoa0901282. View

Saunders M, Liang H, Li W . Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci U S A. 2007; 104(9):3300-5. PMC: 1805605. DOI: 10.1073/pnas.0611347104. View

Zhang H, Yang L, Zhu Y, Yao X, Zhang S, Dai B . Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate. 2010; 71(3):326-31. DOI: 10.1002/pros.21246. View

Gallo A, Tandon M, Alevizos I, Illei G . The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One. 2012; 7(3):e30679. PMC: 3302865. DOI: 10.1371/journal.pone.0030679. View

Sicard F, Gayral M, Lulka H, Buscail L, Cordelier P . Targeting miR-21 for the therapy of pancreatic cancer. Mol Ther. 2013; 21(5):986-94. PMC: 3666633. DOI: 10.1038/mt.2013.35. View

Song B, Wang Y, Titmus M, Botchkina G, Formentini A, Kornmann M . Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer. 2010; 9:96. PMC: 2881118. DOI: 10.1186/1476-4598-9-96. View

To K, Robey R, Knutsen T, Zhan Z, Ried T, Bates S . Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. Mol Cancer Ther. 2009; 8(10):2959-68. PMC: 3680354. DOI: 10.1158/1535-7163.MCT-09-0292. View

10.

Li X, Pan Y, Seigel G, Hu Z, Huang M, Yu A . Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. Biochem Pharmacol. 2011; 81(6):783-92. PMC: 3042498. DOI: 10.1016/j.bcp.2010.12.018. View

11.

Hutvagner G, Zamore P . RNAi: nature abhors a double-strand. Curr Opin Genet Dev. 2002; 12(2):225-32. DOI: 10.1016/s0959-437x(02)00290-3. View

12.

Mekenkamp L, Tol J, Dijkstra J, de Krijger I, Vink-Borger M, van Vliet S . Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer. 2012; 12:292. PMC: 3508829. DOI: 10.1186/1471-2407-12-292. View

13.

Yang H, Kong W, He L, Zhao J, ODonnell J, Wang J . MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008; 68(2):425-33. DOI: 10.1158/0008-5472.CAN-07-2488. View

14.

Pan Y, Zhou A, Hu Z, Yu A . Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos. 2013; 41(10):1744-51. PMC: 3781368. DOI: 10.1124/dmd.113.052092. View

15.

Krishnamurthy P, Ross D, Nakanishi T, Bailey-Dell K, Zhou S, Mercer K . The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem. 2004; 279(23):24218-25. DOI: 10.1074/jbc.M313599200. View

16.

Munoz J, Bliss S, Greco S, Ramkissoon S, Ligon K, Rameshwar P . Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cell-derived Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity. Mol Ther Nucleic Acids. 2013; 2:e126. PMC: 4027430. DOI: 10.1038/mtna.2013.60. View

17.

Liu X, Wang S, Meng F, Wang J, Zhang Y, Dai E . SM2miR: a database of the experimentally validated small molecules' effects on microRNA expression. Bioinformatics. 2012; 29(3):409-11. DOI: 10.1093/bioinformatics/bts698. View

18.

Hwang J, Voortman J, Giovannetti E, Steinberg S, Leon L, Kim Y . Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One. 2010; 5(5):e10630. PMC: 2871055. DOI: 10.1371/journal.pone.0010630. View

19.

Jung E, Santarpia L, Kim J, Esteva F, Moretti E, Buzdar A . Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 2012; 118(10):2603-14. PMC: 3864019. DOI: 10.1002/cncr.26565. View

20.

Vickers K, Palmisano B, Shoucri B, Shamburek R, Remaley A . MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011; 13(4):423-33. PMC: 3074610. DOI: 10.1038/ncb2210. View